RxDoctor Payments Data

Rosane Nunes, MD

Internal Medicine · Deerfield Beach, FLNPI 1295179323

Payments from drug & device makers

$1,816in general payments, 2019–2025

Across 69 payments — averaging $26.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$665
  • Johnson & Johnson$419
  • Amarin Pharma, Inc.$122
  • Novartis$115
  • Lilly USA, LLC$114
  • Amgen$94
  • plus $285 from 6 others

What the payments were for

  • Food & beverage$1,816100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,816 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$13,946
Medicare patients
93
Services billed
156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide31$45,162
MounjaroTirzepatide22$29,008
EliquisApixaban14$21,590
JardianceEmpagliflozin15$18,822
Rosuvastatin Calcium166$2,672
SynthroidLevothyroxine Sodium28$1,971
Levothyroxine Sodium140$1,550
Atorvastatin Calcium164$1,535
Losartan Potassium124$1,475
Valsartan26$1,369
Albuterol Sulfate HfaAlbuterol Sulfate28$1,278
Trazodone Hcl46$976
Metoprolol Succinate85$953
Omeprazole40$782
Escitalopram Oxalate43$779

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$665$45,16231 claims
Lilly USA, LLCMounjaro$114$29,00822 claims
PfizerEliquis$93$21,59014 claims
Boehringer IngelheimJardiance$53$18,82215 claims
AbbVieSynthroid$35$1,97128 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Deerfield Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →